License Agreements - Additional Information (Details) - USD ($)		1 Months Ended			3 Months Ended		6 Months Ended
	Mar. 28, 2022	Mar. 31, 2021	Dec. 31, 2020	Apr. 30, 2020	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 31, 2022	Jan. 31, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Proceeds from stock options exercised							$ 177,000
Pfizer License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone and royalties incurred							0
Upfront payments						$ 5,000,000.0		$ 5,000,000.0
Pfizer License Agreement | Series B Convertible Preferred Stock
Research And Development Arrangement Contract To Perform For Others [Line Items]
Issuance of convertible preferred stock shares						12,152,145		12,152,145
Issuance of convertible preferred stock value					$ 20,000,000.0			$ 20,000,000.0		$ 20,000,000.0
Pfizer License Agreement | Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payment for license fee						$ 25,000,000.0
LegoChem License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Payments to purchase licensed products		$ 9,000,000.0
Estimated cost to purchase licensed products							7,000,000.0
Amount due related to licensed products							0
Amount payable related to licensed products							0
Proceeds from stock options exercised			$ 8,000,000.0
Extra milestone payment			$ 9,600,000
Derivative liability							3,400,000		$ 9,600,000	$ 3,400,000
Fair value adjustment to the derivative liability					$ 2,200,000			$ 3,300,000
Other milestone and royalties incurred							0
Biosion License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone and royalties incurred							$ 0
Aggregate maximum obligation to pay future contingent milestone payments for normal approval	$ 217,500,000
Aggregate maximum obligation to pay future contingent milestone payments for accelerated approval	$ 222,500,000
Royalty obligation period for licensed products upon first commercial sale	12 years
Biosion License Agreement | Research and Development Expenses
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront fee	$ 10,000,000
University License Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Stock issued				48,919
Milestone and royalties incurred									$ 0